| Identifiability of nonrecursive structural equation models M Nagase, Y Kano Statistics & Probability Letters 122, 109-117, 2017 | 38 | 2017 |
| Tumor growth dynamic modeling in oncology drug development and regulatory approval: past, present, and future opportunities N Al‐Huniti, Y Feng, J Yu, Z Lu, M Nagase, D Zhou, J Sheng CPT: pharmacometrics & systems pharmacology 9 (8), 419-427, 2020 | 31 | 2020 |
| Modeling tumor growth and treatment resistance dynamics characterizes different response to gefitinib or chemotherapy in non‐small cell lung cancer M Nagase, S Aksenov, H Yan, J Dunyak, N Al‐Huniti CPT: Pharmacometrics & Systems Pharmacology 9 (3), 143-152, 2020 | 12 | 2020 |
| Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes M Nagase, H Shimada, M Nii, S Ueda, M Higashimori, K Ichikawa, ... Journal of Clinical Pharmacy and Therapeutics 45 (5), 1030-1038, 2020 | 6 | 2020 |
| A multistate platform model for time‐to‐event endpoints in oncology clinical trials CW Lin, M Nagase, S Doshi, S Dutta CPT: Pharmacometrics & Systems Pharmacology 13 (1), 154-167, 2024 | 2 | 2024 |
| Estimation of time to progression and post progression survival using joint modeling of summary level OS and PFS data with an ordinary differential equation model M Nagase, S Doshi, S Dutta, CW Lin Journal of Pharmacokinetics and Pharmacodynamics 49 (4), 455-469, 2022 | 2 | 2022 |
| Cyclic structural causal model with unobserved confounder effect M Nagase, Y Kano Communications in Statistics-Theory and Methods 52 (2), 335-345, 2023 | 1 | 2023 |
| Population Pharmacokinetics of Sotorasib in Healthy Subjects and Advanced Solid Tumor Patients Harboring a KRASG12C Mutation from Phase 1 and Phase 2 … M Nagase, B Houk, I Vuu, P Cardona, S Dutta, CW Lin The AAPS Journal 27 (1), 26, 2025 | | 2025 |
| ITEM RESPONSE THEORY MODELING FRAMEWORK FOR EVALUATING MIGRAINE-SPECIFIC QUESTIONNAIRE (MSQ) IN MIGRAINE DRUG DEVELOPMENT. P Chen, A Pritchard-Bell, M Karlsson, S Ueckert, C Davis, M Nagase, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 111, S14-S14, 2022 | | 2022 |
| Optimal designs for regional bridging studies using the Bayesian power prior method M Nagase, S Ueda, M Higashimori, K Ichikawa, J Dunyak, N Al‐Huniti Pharmaceutical Statistics 19 (1), 22-30, 2020 | | 2020 |
| SB1-2 Causal discovery of cyclic nonlinear relations Cyclic non-linear structure equation models with additive normal noise M Nagase, Y Kano Proceedings of the Annual Meeting of the Behaviormetric Society of Japan 47 …, 2019 | | 2019 |
| A BAYESIAN METHOD FOR THE MODELING, DESIGN, AND ANALYSIS OF DRUG DEVELOPMENT BRIDGING STUDIES ACROSS GEOGRAPHIES. M Nagase, J Dunyak, N Al-Huniti CLINICAL PHARMACOLOGY & THERAPEUTICS 105, S64-S64, 2019 | | 2019 |
| Cyclic Structural Equation Models and Their Identifiability M Nagase, Y Kano Proceedings of The ISI Regional Statistics Conference 2017 (ISI RSC 2017 …, 2017 | | 2017 |
Yutaka KanoDoshisha UniversityEmail verificata su mail.doshisha.ac.jp
Yutaka KanoDoshisha UniversityEmail verificata su mail.doshisha.ac.jp